Jessica Wedig, Shrina Jasani, Debasmita Mukherjee, Hannah Lathrop, Priya Matreja, Timothy Pfau, Liliana D'Alesio, Abigail Guenther, Lexie Fenn, Morgan Kaiser, Molly A Torok, Jake McGue, Gina M Sizemore, Anne M Noonan, Mary E Dillhoff, Bradley W Blaser, Timothy L Frankel, Stacey Culp, Phil A Hart, Zobeida Cruz-Monserrate, Thomas A Mace
Pancreatic cancer is an aggressive disease with a 5 year survival rate of 13%. This poor survival is attributed, in part, to limited and ineffective treatments for patients with metastatic disease, highlighting a need to identify molecular drivers of pancreatic cancer to target for more effective treatment. CD200 is a glycoprotein that interacts with the receptor CD200R and elicits an immunosuppressive response. Overexpression of CD200 has been associated with differential outcomes, depending on the tumor type...
April 15, 2024: Cancer Immunology, Immunotherapy: CII